FDC Ltd

FDC Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

FDC Ltd

₹ 388 2.36%
12 Jun - close price
fdcindia.com BSE: 531599 NSE: FDC
About

FDC (Fairdeal Corporation) Ltd Limited (found in 1936) is among India’s leading fully integrated pharmaceutical companies. The Company is a pioneer in the manufacture of specialized formulations, and among the world’s foremost manufacturers and marketers of Oral Rehydration Salts (ORS). Some of FDC’s leading brands in India include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zathrin, Zipod, Cotaryl and Mycoderm in the domestic and international markets.[1]

Key Points

Revenue Breakup FY25[1]
Formulations: 92%,
Bulk Drugs : 6%,
Profit share - Formulation: 2%

Website BSE NSE
  • Market Cap ₹ 6,315 Cr.
  • Current Price ₹ 388
  • High / Low ₹ 528 / 313
  • Stock P/E 21.3
  • Book Value ₹ 153
  • Dividend Yield 1.29 %
  • ROCE 16.7 %
  • ROE 12.5 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 19.8%

Cons

  • The company has delivered a poor sales growth of 10.3% over past five years.
  • Company has a low return on equity of 12.8% over last 3 years.
  • Working capital days have increased from 68.7 days to 121 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE 1000

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
435 536 486 458 462 638 514 464 492 648 473 465 585
386 414 410 374 406 492 444 417 438 508 439 412 478
Operating Profit 49 122 76 84 56 147 70 47 54 140 34 52 106
OPM % 11% 23% 16% 18% 12% 23% 14% 10% 11% 22% 7% 11% 18%
7 29 27 25 20 28 35 19 16 36 21 0 50
Interest 1 1 1 1 1 1 1 1 1 1 1 1 2
Depreciation 10 10 10 10 10 11 14 13 16 15 15 15 14
Profit before tax 45 141 93 98 65 163 90 51 53 160 38 36 140
Tax % 32% 22% 25% 19% 29% 27% 20% 28% 27% 24% 26% 22% 26%
31 110 70 79 46 119 72 37 39 121 28 28 103
EPS in Rs 1.85 6.62 4.29 4.87 2.84 7.31 4.42 2.28 2.38 7.45 1.74 1.74 6.35
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
888 994 1,013 1,074 1,089 1,341 1,331 1,525 1,784 1,943 2,108 2,171
690 765 769 841 860 1,038 997 1,271 1,533 1,604 1,783 1,825
Operating Profit 199 229 243 233 229 304 334 254 251 339 325 346
OPM % 22% 23% 24% 22% 21% 23% 25% 17% 14% 17% 15% 16%
46 39 44 45 42 57 95 76 50 102 91 93
Interest 2 1 1 1 1 3 3 3 4 4 5 5
Depreciation 39 34 35 35 33 37 38 37 39 40 54 59
Profit before tax 204 232 252 241 237 320 388 289 258 396 357 375
Tax % 27% 27% 25% 28% 28% 25% 22% 25% 25% 23% 25% 25%
148 169 189 174 170 240 301 216 194 305 267 281
EPS in Rs 8.33 9.48 10.60 9.95 9.74 14.03 17.85 12.82 11.70 18.75 16.39 17.29
Dividend Payout % 27% 24% 21% 0% 0% 6% 0% 0% 0% 0% 31% 29%
Compounded Sales Growth
10 Years: 8%
5 Years: 10%
3 Years: 7%
TTM: 3%
Compounded Profit Growth
10 Years: 6%
5 Years: 1%
3 Years: 16%
TTM: 15%
Stock Price CAGR
10 Years: 8%
5 Years: 0%
3 Years: 8%
1 Year: -18%
Return on Equity
10 Years: 13%
5 Years: 12%
3 Years: 13%
Last Year: 12%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 18 18 18 18 18 17 17 17 17 16 16 16
Reserves 919 1,065 1,252 1,259 1,428 1,530 1,717 1,940 1,965 2,081 2,265 2,469
2 1 1 1 1 15 15 32 28 21 21 15
210 182 197 228 194 250 207 281 333 350 412 418
Total Liabilities 1,148 1,266 1,468 1,505 1,640 1,813 1,956 2,270 2,343 2,468 2,714 2,919
393 675 678 674 682 674 689 705 699 680 852 1,000
CWIP 29 20 6 13 12 24 19 105 198 261 137 96
Investments 489 325 491 471 585 665 790 886 806 843 1,028 1,048
237 246 293 348 360 451 458 575 640 684 698 775
Total Assets 1,148 1,266 1,468 1,505 1,640 1,813 1,956 2,270 2,343 2,468 2,714 2,919

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
128 174 154 150 112 250 207 162 155 221 318 200
-89 -73 -144 21 -121 -98 -77 -145 11 -17 -199 -110
-48 -97 0 -169 -0 -142 -129 -10 -180 -202 -92 -93
Net Cash Flow -9 4 11 1 -8 10 1 7 -14 2 26 -3
Free Cash Flow 83 -130 130 114 70 247 148 35 47 151 227 40
CFO/OP 96% 101% 92% 94% 81% 110% 90% 95% 93% 96% 129% 83%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 25 23 27 28 29 34 30 20 25 22 19 26
Inventory Days 132 134 148 166 184 180 189 210 183 216 186 182
Days Payable 94 84 81 101 82 101 68 94 99 103 102 106
Cash Conversion Cycle 64 72 94 93 131 113 152 135 109 135 103 102
Working Capital Days 11 21 23 29 45 40 48 45 48 53 33 121
ROCE % 21% 22% 21% 19% 17% 21% 22% 15% 13% 18% 16% 17%

Insights

In beta
Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Number of Medical Representatives (Field Force)
Count ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Market Share - Electral (ORS)
% ・Standalone data
Market Share - Zifi (Cefixime)
% ・Standalone data
Number of Dealers/Distributors
Count ・Standalone data
Market Share - Enerzal
% ・Standalone data
Monthly Production Capacity - Sinnar ORS Sachets
Million Units ・Standalone data
US FDA Approved ANDAs (Cumulative)
Count ・Standalone data
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
69.49% 69.66% 69.66% 69.66% 69.66% 69.66% 69.66% 69.66% 69.66% 69.66% 69.66% 69.65%
2.06% 2.42% 2.43% 2.65% 2.51% 2.62% 2.67% 2.56% 2.41% 2.43% 2.32% 2.40%
9.13% 8.12% 7.76% 6.94% 6.72% 6.02% 6.08% 6.37% 7.17% 6.81% 6.27% 6.29%
19.32% 19.80% 20.15% 20.76% 21.11% 21.71% 21.60% 21.42% 20.76% 21.10% 21.76% 21.65%
No. of Shareholders 56,71756,92855,34152,37750,63455,40055,22853,88054,44554,15753,78852,730

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls